TagCyx is a research based company based in Tokyo (Japan), founded in March 2007 as a spin out company of RIKEN.
TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 7, 2021 | Series Unknown | ¥210M | 3 | — | — | Detail |
Apr 27, 2020 | Series Unknown | ¥200M | 1 | — | — | Detail |
Apr 24, 2018 | Series B | ¥500.25M | 4 | — | — | Detail |
Aug 31, 2016 | Series Unknown | ¥500M | 3 | UTEC - The University of Tokyo Edge Capital Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Healthcare Innovation | — | Series Unknown |
SBI Group | — | Series Unknown |
UTokyo Innovation Platform | — | Series Unknown |
Mizuho Capital | — | Series B |
SMBC Venture Capital | — | Series B |
UTEC - The University of Tokyo Edge Capital Partners | — | Series B |
Nissay Capital | — | Series Unknown |